View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBod Science 配当と自社株買い配当金 基準チェック /06Bod Science配当金を支払った記録がありません。主要情報n/a配当利回り-82.1%バイバック利回り総株主利回り-82.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 10Bod Science Limited announced that it expects to receive AUD 2.05 million in fundingBod Science Limited announced a private placement of 68,333,333 fully paid ordinary shares at an issue price of AUD 0.03 per share for the gross proceeds of AUD 2,049,999.99 on November 8, 2023. The company will raise the funding in two tranches. The company will issue of 26,600,000 shares for the gross proceeds of AUD 80,000 in the first tranche and 41,700,000 shares for the gross proceeds of AUD 1,250,000 in second tranche. Tranche 2 includes the proposed issue of AUD 30,000 worth of shares to Jo Patterson subject to shareholder approval. Assuming Tranche 2 is approved, the transaction will involve the issue of 68.3 million shares. The transaction will include participation from new investor Antah Healthcare Group through a commitment of AUD 1,100,000 worth of shares. On completion of the transaction, it is expected that Antah Healthcare Group will hold a relevant interest of 14.9% of company's issued shares.お知らせ • Nov 09Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,600,773 Price\Range: AUD 0.03 Security Name: Shares Security Type: Common Stock Securities Offered: 41,732,556 Price\Range: AUD 0.03 Transaction Features: Subsequent Direct ListingBoard Change • Nov 08No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 07Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,751,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,875,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 02Bod Science Limited, Annual General Meeting, Nov 27, 2023Bod Science Limited, Annual General Meeting, Nov 27, 2023. Agenda: To consider and approve the re-election of Directors.Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.New Risk • Aug 31New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$703k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$703k). Earnings have declined by 4.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$12.3m market cap, or US$7.94m). Minor Risk Revenue is less than US$5m (AU$3.6m revenue, or US$2.4m).New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$9.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.1m revenue, or US$2.6m).New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Market cap is less than US$10m (AU$12.8m market cap, or US$8.31m). Minor Risk Revenue is less than US$5m (AU$4.1m revenue, or US$2.7m).お知らせ • Aug 11Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.Bod Australia Limited (ASX:BOD) entered into binding agreement to acquire Aqua Phase Ltd for £3 million on August 30, 2022. Bod will pay total consideration of £3 million with Initial payment of £1 million in cash to be paid upon satisfaction of conditions precedent relating to successful completion of upcoming manufacture, stability and bioavailability testing. Remaining consideration paid against further milestone achievements relating to pharmaceutical GMP manufacture and commercialization, with optionality for Bod to pay in cash or shares over a 12-36 month timeframe. The earnout payments are conditional upon ASX and shareholder's approval. As on March 7, 2023, Bod has successfully completed the stability testing of the Aqua Phase product format within the agreed time frame, along with the manufacture of a technical batch per the acquisition terms and timeframe. Due to third party delays involved in the testing and analyzing phase of the PK study, Bod Science has agreed with the Inventors to extend the date by which this test must be completed to June 30, 2023. As on March 28, 2023, Bod Science is pleased to report the PK study to confirm the bioavailability of Aqua Phase has been submitted for ethics approval, with approval expected within 2 weeks. Recruitment for study participants will commence immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd on August 10, 2023.Board Change • Jun 01No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 02No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Jan 24Bod Science Limited Announces Company Secretary ChangesBod Science Limited announced the appointment of Carlie Hodges as Company Secretary upon the resignation of Stephen Kelly, effective 23 January 2023. Carlie is a practising corporate and commercial lawyer, holds a Graduate Diploma in Applied Corporate Governance and is a Fellow Member of the Governance Institute of Australia.Board Change • Dec 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Oct 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Oct 08Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Aug 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jun 04Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 03Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman Mark Masterson was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Mar 01First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Board Change • Feb 24High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Dec 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 25Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Executive Departure • Apr 02Chief Financial Officer has left the companyOn the 29th of March, Charles Altshuler's tenure as Chief Financial Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Charles' name. Charles is the only executive to leave the company over the last 12 months.Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 34% from its price of AU$0.62 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is flat over the same period.Is New 90 Day High Low • Feb 01New 90-day low: AU$0.42The company is down 13% from its price of AU$0.48 on 04 November 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 1.0% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: AU$0.58The company is up 107% from its price of AU$0.28 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 15New 90-day high: AU$0.51The company is up 94% from its price of AU$0.26 on 17 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 41% over the same period.Is New 90 Day High Low • Sep 29New 90-day high: AU$0.40The company is up 46% from its price of AU$0.27 on 01 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 16% over the same period.決済の安定と成長配当データの取得安定した配当: BODの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BODの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Bod Science 配当利回り対市場BOD 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BOD)n/a市場下位25% (AU)2.7%市場トップ25% (AU)6.6%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (BOD) (最長3年)n/a注目すべき配当: BODは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BODは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BODの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BODが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YAU 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/20 22:57終値2023/11/23 00:00収益2023/06/30年間収益2023/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bod Science Limited これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alexander SmithPAC Partners Securities Pty. Ltd.
お知らせ • Nov 10Bod Science Limited announced that it expects to receive AUD 2.05 million in fundingBod Science Limited announced a private placement of 68,333,333 fully paid ordinary shares at an issue price of AUD 0.03 per share for the gross proceeds of AUD 2,049,999.99 on November 8, 2023. The company will raise the funding in two tranches. The company will issue of 26,600,000 shares for the gross proceeds of AUD 80,000 in the first tranche and 41,700,000 shares for the gross proceeds of AUD 1,250,000 in second tranche. Tranche 2 includes the proposed issue of AUD 30,000 worth of shares to Jo Patterson subject to shareholder approval. Assuming Tranche 2 is approved, the transaction will involve the issue of 68.3 million shares. The transaction will include participation from new investor Antah Healthcare Group through a commitment of AUD 1,100,000 worth of shares. On completion of the transaction, it is expected that Antah Healthcare Group will hold a relevant interest of 14.9% of company's issued shares.
お知らせ • Nov 09Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,600,773 Price\Range: AUD 0.03 Security Name: Shares Security Type: Common Stock Securities Offered: 41,732,556 Price\Range: AUD 0.03 Transaction Features: Subsequent Direct Listing
Board Change • Nov 08No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 07Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,751,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,875,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 02Bod Science Limited, Annual General Meeting, Nov 27, 2023Bod Science Limited, Annual General Meeting, Nov 27, 2023. Agenda: To consider and approve the re-election of Directors.
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)Full year 2023 results: AU$0.056 loss per share (further deteriorated from AU$0.051 loss in FY 2022). Revenue: AU$3.64m (down 28% from FY 2022). Net loss: AU$7.95m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 31New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$703k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$703k). Earnings have declined by 4.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$12.3m market cap, or US$7.94m). Minor Risk Revenue is less than US$5m (AU$3.6m revenue, or US$2.4m).
New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$9.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.1m revenue, or US$2.6m).
New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Market cap is less than US$10m (AU$12.8m market cap, or US$8.31m). Minor Risk Revenue is less than US$5m (AU$4.1m revenue, or US$2.7m).
お知らせ • Aug 11Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.Bod Australia Limited (ASX:BOD) entered into binding agreement to acquire Aqua Phase Ltd for £3 million on August 30, 2022. Bod will pay total consideration of £3 million with Initial payment of £1 million in cash to be paid upon satisfaction of conditions precedent relating to successful completion of upcoming manufacture, stability and bioavailability testing. Remaining consideration paid against further milestone achievements relating to pharmaceutical GMP manufacture and commercialization, with optionality for Bod to pay in cash or shares over a 12-36 month timeframe. The earnout payments are conditional upon ASX and shareholder's approval. As on March 7, 2023, Bod has successfully completed the stability testing of the Aqua Phase product format within the agreed time frame, along with the manufacture of a technical batch per the acquisition terms and timeframe. Due to third party delays involved in the testing and analyzing phase of the PK study, Bod Science has agreed with the Inventors to extend the date by which this test must be completed to June 30, 2023. As on March 28, 2023, Bod Science is pleased to report the PK study to confirm the bioavailability of Aqua Phase has been submitted for ethics approval, with approval expected within 2 weeks. Recruitment for study participants will commence immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd on August 10, 2023.
Board Change • Jun 01No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 02No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$2.57m (down 25% from 1H 2022). Net loss: AU$3.17m (loss widened 46% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Jan 24Bod Science Limited Announces Company Secretary ChangesBod Science Limited announced the appointment of Carlie Hodges as Company Secretary upon the resignation of Stephen Kelly, effective 23 January 2023. Carlie is a practising corporate and commercial lawyer, holds a Graduate Diploma in Applied Corporate Governance and is a Fellow Member of the Governance Institute of Australia.
Board Change • Dec 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Oct 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Oct 08Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Aug 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jun 04Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Akash Bedi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 03Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Member of Medical Advisory Board Nick Burgess is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman Mark Masterson was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Mar 01First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.02 loss per share (down from AU$0.014 loss in 1H 2021). Revenue: AU$3.44m (up 4.0% from 1H 2021). Net loss: AU$2.17m (loss widened 68% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Board Change • Feb 24High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Dec 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Simon O'Loughlin is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 25Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$7.53m (up 27% from FY 2020). Net loss: AU$4.23m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Executive Departure • Apr 02Chief Financial Officer has left the companyOn the 29th of March, Charles Altshuler's tenure as Chief Financial Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Charles' name. Charles is the only executive to leave the company over the last 12 months.
Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 34% from its price of AU$0.62 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is flat over the same period.
Is New 90 Day High Low • Feb 01New 90-day low: AU$0.42The company is down 13% from its price of AU$0.48 on 04 November 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: AU$0.58The company is up 107% from its price of AU$0.28 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 15New 90-day high: AU$0.51The company is up 94% from its price of AU$0.26 on 17 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 41% over the same period.
Is New 90 Day High Low • Sep 29New 90-day high: AU$0.40The company is up 46% from its price of AU$0.27 on 01 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 16% over the same period.